Please assess the completion status of the following clinical trial:

Trial Title: A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patient with histologically proven, measurable metastatic cutaneous melanoma~2. Written informed consent has been obtained from the patient before the performance of any protocol-specific procedure.~3. Patient is \>= 18 years of age at the time of signature of the Informed Consent.~4. The patient's tumor shows expression of MAGE-A3 antigen, detected by Reverse-Transcription Polymerase Chain Reaction (RT-PCR).~5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.~6. The patient has normal organ functions.~7. If the patient is female, she must be of non-childbearing potential, or, if she is of childbearing potential, she must practice adequate contraception for 30 days prior to administration of study treatment, have a negative pregnancy test and continue such precautions during all the study treatment period and for 2 months after completion of the treatment administration series.~8. In the view of the investigator, the patient can and will comply with the requirements of the protocol.~Exclusion Criteria:~1. The patient has at any time received systemic (bio)-chemotherapy.~2. The patient is scheduled to receive any other anticancer treatments than those specified in the protocol, including but not limited to (bio)-chemotherapy, immunomodulating agents and radiotherapy.~3. The patient requires concomitant treatment with systemic corticosteroids, or any other immunosuppressive agents.~4. The patient received any cancer immunotherapeutic containing a MAGE-A3 antigen or any cancer immunotherapeutic for his/her metastatic disease.~5. The patient has received any investigational or non-registered drug or vaccine other than the study medication within the 30 days preceding the first dose of study treatment, or plans to receive such a drug during the study period.~6. The patient has (or has had) previous or concomitant malignancies at other sites, except effectively treated malignancy that is considered by the investigator highly likely to have been cured.~7. History of allergic disease or reactions likely to be exacerbated by any component of the study investigational product.~8. The patient has an autoimmune disease such as, but not limited to, multiple sclerosis, lupus, and inflammatory bowel disease. Patients with vitiligo are not excluded.~9. The patient has a family history of congenital or hereditary immunodeficiency.~10. The patient is known to be positive for the Human Immunodeficiency Virus (HIV).~11. The patient has psychiatric or addictive disorders that may compromise his/her ability to give informed consent, or to comply with the trial procedures.~12. The patient has concurrent severe medical problems, unrelated to the malignancy, that would significantly limit full compliance with the study or expose the patient to unacceptable risk.~13. For female patients: the patient is pregnant or lactating.~14. The patient has an uncontrolled bleeding disorder.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): All patients are to receive the same treatment consisting of 24 injections of the immunotherapeutic GSK2132231A combined with a course of 8 cycles of dacarbazine given at the beginning of the treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy